Carde P
Institut Gustave-Roussy, Villejuif, France.
Nouv Rev Fr Hematol (1978). 1990;32(2):169-73.
Chemotherapy is the main treatment for advanced Hodgkin's disease as demonstrated by the NCI MOPP study. The main prognostic factors have been identified. ABVD is partially non cross-resistant and permits the alteration of two regimens in order to achieve greater efficacy. The respective impact of conventional and high-dose chemotherapy for salvage treatment is being evaluated. Long-term hazards due to different regimens require continuous assessment so that the choice and modalities of chemotherapy in localized disease may be determined.